Apomorphine induced hemolytic anemia: A case report and literature review
Objective: To present a case of apomorphine induced hemolytic anemia Background: Drug induced immune hemolytic anemia (DIIHA) is a potentially lethal adverse reaction; It has…Population Exposure-Response Models of Apomorphine Sublingual Film in Healthy Subjects and Patients With Parkinson’s Disease and “OFF” Episodes
Objective: Exposure-response models were developed to characterize the relationship between apomorphine exposure and (1) efficacy using Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease…Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the efficacy of APL-130277 (APL) in a double-blind, placebo-controlled trial. Background: OFF episodes are a common, disabling complication of Parkinson’s disease (PD)…Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial
Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…Treatment of Levodopa Dose Failure with Subcutaneous Apomorphine Injection
Objective: We evaluated a subset of patients who were enrolled in the AMIMPAKT trial of sc apomorphine injection to treat morning akinesia (see reference) who…Patient’s Choice of Device-Based Treatments in Parkinson’s Disease
Objective: Deep brain stimulation of subtalamic nucleus (STN-DBS), subcutaneous apomorphine infusion (APO) and levodopa-carbidopa intestinal gel infusion (DUO) is routinely used in patients with advanced…Atypical Response to Apomorphine in a Patient with Multiple System Atrophy
Objective: Multiple system atrophy (MSA) is a sporadic neurodegenerative disease clinically characterized by cerebellar signs, parkinsonism and autonomic dysfunction. MSA is classified into two sub-types;…Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson’s disease(PD) from OFF to fully ON: Preliminary Results from a Phase III Study
Objective: To determine if baseline disease severity could be correlated to the effective dose of APL-130277 that was required to turn a patient with PD…ND0701: A new concentrated formulation of Apomorphine for continuous subcutaneous administration – human PK data
Objective: To evaluate the PK and relative bioavailability of ND0701, a subcutaneously (SC) infused apomorphine-base product candidate, and a commercial apomorphine-HCl product. The secondary objective…Pharmaeconomic study of the treatment of advanced Parkinson’s disease.
Objective: Conduct a comparative pharmacoeconomic analysis of the use of subcutaneous apomorphine infusion pump (SAIP), continuous levodopa/carbidopa duodenal infusión (LDI) and deep brain stimulation (DBS). Background:…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »